BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 32438373)

  • 1. Retrospective analysis of eligibility for denosumab in patients presenting with osteoporotic fractures and renal impairment treated by orthogeriatric service at Middlemore Hospital.
    Kang MY; Besley J; Sun T; Paul S
    N Z Med J; 2020 May; 133(1515):16-24. PubMed ID: 32438373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoporosis prevalence and characteristics of treated and untreated nursing home residents with osteoporosis.
    Zarowitz BJ; Cheng LI; Allen C; O'Shea T; Stolshek B
    J Am Med Dir Assoc; 2015 Apr; 16(4):341-8. PubMed ID: 25726417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of bone protection and associated fragility injuries in patients with proximal femur fractures.
    Aguado-Maestro I; Panteli M; García-Alonso M; Bañuelos-Díaz A; Giannoudis PV
    Injury; 2017 Dec; 48 Suppl 7():S27-S33. PubMed ID: 28851521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alendronate use in older patients with reduced renal function: challenges and opportunities in clinical practice.
    Naganathar N; Yau W-; Mok ZH; Tan ZYF; Chew STH
    Osteoporos Int; 2021 Oct; 32(10):1981-1988. PubMed ID: 33721033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventing future fractures: effectiveness of an orthogeriatric fracture liaison service compared to an outpatient fracture liaison service and the standard management in patients with hip fracture.
    Naranjo A; Fernández-Conde S; Ojeda S; Torres-Hernández L; Hernández-Carballo C; Bernardos I; Rodríguez S; Laynez P
    Arch Osteoporos; 2017 Dec; 12(1):112. PubMed ID: 29230540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal impairment among postmenopausal women with osteoporosis from a large health plan in Israel.
    Yu J; Goldshtein I; Shalev V; Chodick G; Ish-Shalom S; Sharon O; Modi A
    Arch Osteoporos; 2015; 10():210. PubMed ID: 25753617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs.
    Iwamoto N; Okamoto M; Tsuji S; Endo Y; Takatani A; Shimizu T; Umeda M; Fukui S; Sumiyoshi R; Igawa T; Koga T; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Nakamura H; Origuchi T; Eguchi K; Ueki Y; Kawakami A
    J Bone Miner Metab; 2019 May; 37(3):554-562. PubMed ID: 30187273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
    Miller PD; Roux C; Boonen S; Barton IP; Dunlap LE; Burgio DE
    J Bone Miner Res; 2005 Dec; 20(12):2105-15. PubMed ID: 16294264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Status quo of osteoporosis treatment in Japan disclosed by the National Database of Health Insurance Claims and Specific Health Checkups: too late in treatment initiation and too few in treated patients?
    Kamata Y; Minota S
    Arch Osteoporos; 2019 Jul; 14(1):84. PubMed ID: 31367957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low rate of densitometric diagnosis and treatment in patients with severe osteoporosis in Colombia.
    Fernández-Ávila DG; Rincón-Riaño DN; Pinzón DF; Gutiérrez Dávila JM
    Arch Osteoporos; 2019 Sep; 14(1):95. PubMed ID: 31486920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MANAGEMENT OF ENDOCRINE DISEASE: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy.
    Adler RA
    Eur J Endocrinol; 2018 Mar; 178(3):R81-R87. PubMed ID: 29339529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of a coordinated management of osteoporosis via Fracture Liaison Service for the treatment of orthogeriatric patients.
    Schray D; Neuerburg C; Stein J; Gosch M; Schieker M; Böcker W; Kammerlander C
    Eur J Trauma Emerg Surg; 2016 Oct; 42(5):559-564. PubMed ID: 27458065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation.
    Pedersen AB; Heide-Jørgensen U; Sørensen HT; Prieto-Alhambra D; Ehrenstein V
    JAMA Netw Open; 2019 Apr; 2(4):e192416. PubMed ID: 31002319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
    Saag KG; Pannacciulli N; Geusens P; Adachi JD; Messina OD; Morales-Torres J; Emkey R; Butler PW; Yin X; Lems WF
    Arthritis Rheumatol; 2019 Jul; 71(7):1174-1184. PubMed ID: 30816640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Efficacy of Alendronate Versus Denosumab on Major Osteoporotic Fracture Risk in Elderly Patients With Diabetes Mellitus: A Danish Retrospective Cohort Study.
    Viggers R; Al-Mashhadi Z; Starup-Linde J; Vestergaard P
    Front Endocrinol (Lausanne); 2021; 12():826997. PubMed ID: 35154013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective analysis of nonresponse to denosumab after hip fractures.
    Kim SJ; Lee DW
    Acta Orthop Belg; 2023 Mar; 89(1):71-76. PubMed ID: 37294988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary prevention of osteoporotic fractures: evaluation of the Lille University Hospital's Fracture Liaison Service between January 2016 and January 2018.
    Pflimlin A; Gournay A; Delabrière I; Chantelot C; Puisieux F; Cortet B; Paccou J
    Osteoporos Int; 2019 Sep; 30(9):1779-1788. PubMed ID: 31190123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap.
    Ban JK; Hao BB; McCarthy L; Guilcher SJT; Cadarette SM
    Osteoporos Int; 2019 Sep; 30(9):1865-1872. PubMed ID: 31317248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
    Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
    Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.